Recalls & Warnings
ConsumerLab.com is keeping you informed with current product recalls and warnings.
Latest Posted November 28, 2022
On November 14, 2022, the FDA issued a warning letter to The Truth Company, LLC (parent company of Kinobody, LLC and UMZU, LLC) following inspection of the company’s websites which found statements about its Betaine, Immune, Redwood, Sensolin, Thyrite, zuRelief, Kino Aminos, Kino Collagen Protein, and Kino Gains products to be drug claims.
For example, Betaine HCl products were promoted with statements such as, “Betaine has been shown in research to also improve... and even diabetes prevention.” Additionally, zuRelief was promoted to “reduce pain,” including a supposed statement from an MD, which says, “I am an MD and there is no product on the conventional over the counter market that approaches the combination of safety and effectiveness of zuRelief for my own joint and muscle aches.”
(See ConsumerLab’s article about UMZU’s zuPOO supplement, promoted to cleanse the gut and improve digestion.)
Several of the company’s products were also found to be misbranded because the labels did not provide adequate directions for their intended use.
The company must respond to the FDA within 15 days outlining the steps taken to address any violations.
See ConsumerLab’s Joint Health, Collagen, and Curcumin and Turmeric Reviews for more information and tests of related products.
For more information, use the link below.
Warning: The Truth Company, LLC
See related recalls and warnings:
Walmart Inc. Recalls Joint Supplements With Omega-3, Glucosamine & Curcumin
Collagen & Biotin Supplement Recalled Due to Allergen Risk
Fountain of Youth Formula Collagen Protein Recalled
Living Free Vitamins, Joint, Nerve and Other Supplements Recalled
FDA Warns Muscle Sports for Joint Health, Immune & Workout Supplement, Vitamin C, Elderberry, and Other Claims
For information about reporting serious reactions and problems with medical products to the U.S. Food and Drug Administration through its MedWatch reporting program, please visit the FDA MedWatch website.